Genentech's cancer drug Avastin received FDA approval for advanced renal cell carcinoma, the most common type of kidney cancer. The product already is approved for several forms of lung, breast and colon cancers.
Published in Brief:
|Chief Operating Officer||
Presence Health Partners
|Des Plaines, IL|
|Sr. Business Systems Analyst||
|Sr. Reimbursement Analyst||
Olympus America Inc.
|Staff VP Medical Policy Development-81321||
|Strategic Partner Relationship Executive||
Geisinger Health System